Navigation Links
Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
Date:2/11/2010

PARSIPPANY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI) announced today that Jay M. Feingold, M.D., Ph.D., has been appointed Vice President of Medical Affairs. Dr. Feingold will manage strategic direction of the company's Medical Affairs department and oversee more than 90 scientists, researchers and field-based medical teams responsible for collaborating with the company's clinical research arm, commercial organization and partners. Medical Affairs is responsible for providing physicians, key opinion leaders, regulatory agencies and professional organizations with medical and scientific information in the areas of clinical studies, outcomes research and disease management programs, among others. Dr. Feingold's vast experience in oncology and hematology will continue to drive the company's current cardiovascular portfolio and shape its pipeline.

"I am very excited to join Daiichi Sankyo and look forward to working with my colleagues to continue to build relationships with health care providers to improve medical care and enhance professional education," said Dr. Feingold. "As we develop new and innovative therapies it will be important to ensure that critical safety and efficacy information is understood by practitioners, regulatory agencies, payors and patients. Medical Affairs plays a key role in communicating this information."

Dr. Feingold also becomes a member of DSI's Executive Committee, which is responsible for guiding the organization's short- and long-term strategic and financial objectives.

DSI is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd. The U.S. headquarters facility in Parsippany, New Jersey houses 480 employees, including corporate offices and all functions that support the company's commercial operations. In addition, the company has a clinical development division in Edison, New Jersey that employs 350 people who oversee clinical trials being conducted around the world.    

Prior to joining DSI, Dr. Feingold worked with Wyeth Pharmaceuticals, where he most recently led Oncology Global Clinical Development.  Prior to that, he was multi-therapeutic area head in Global Medical Affairs with responsibility for the hematology, oncology and central nervous system (CNS) franchises.

Dr. Feingold, a member of the American Society of Hematology and American Society of Clinical Oncology, is a molecular biologist who earned his Bachelor of Science degree from S.U.N.Y. Stony Brook and his Medical Degree, Master of Science and Ph.D. degrees from Albert Einstein College of Medicine.  Dr. Feingold did his residency in Pediatrics and fellowship in Pediatric Hematology/Oncology at the UCLA Center for the Health Sciences.

About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator.  The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies.  This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research

and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit www.dsi.com.

SOURCE Daiichi Sankyo, Inc.

RELATED LINKS
http://www.dsi.com

'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
4. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
5. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
6. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
7. KGI Names Kerry Howell Vice President for Advancement
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. CryoLife Names Philip Theodore as Vice President, General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, former senior ... the University of North Carolina Kenan-Flagler Business School effective June 27. ... Kenan-Flagler, with a focus on the school’s international efforts, leading classes and participating ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
Breaking Biology Technology:
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):